Do analysts prefer SPRO or BRNS?

Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 531.91%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BRNS or BMEA more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -63.83% -48.77% Biomea Fusion N/A -265.37% -103.96%

Which has higher earnings & valuation, BRNS or SXTC?

China SXT Pharmaceuticals has lower revenue, but higher earnings than Barinthus Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Barinthus Biotherapeutics $14.97M 1.73 -$66.43M -$1.29 N/A China SXT Pharmaceuticals $1.14M 89.85 -$6.20M N/A N/A

Is BRNS or SXTC more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -63.83% -48.77% China SXT Pharmaceuticals N/A N/A N/A

Is ACRV or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Barinthus Biotherapeutics N/A -63.83% -48.77%

Barinthus Biotherapeutics (BRNS) Competitors

$0.63 +0.02 (+2.59%)

Closing price 03:59 PM Eastern

Extended Trading

$0.63 0.00 (0.00%)

As of 04:08 PM Eastern

Compare

BRNS vs. SPRO, AADI, BMEA, SXTC, and ACRV

Should you buy Barinthus Biotherapeutics stock or one of its competitors? MarketBeat compares Barinthus Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Barinthus Biotherapeutics include Spero Therapeutics (SPRO), Aadi Bioscience (AADI), Biomea Fusion (BMEA), China SXT Pharmaceuticals (SXTC), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry.

How does Barinthus Biotherapeutics compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Spero Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market.

Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 531.91%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Spero Therapeutics has higher revenue and earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.20	$8.57M	$0.24	5.75
Barinthus Biotherapeutics	$14.97M	1.73	-$66.43M	-$1.29	N/A

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Spero Therapeutics had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 0 mentions for Barinthus Biotherapeutics. Spero Therapeutics' average media sentiment score of 0.43 beat Barinthus Biotherapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Neutral
Barinthus Biotherapeutics	Neutral

Spero Therapeutics has a net margin of 24.90% compared to Barinthus Biotherapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Summary

Spero Therapeutics beats Barinthus Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Aadi Bioscience?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aadi Bioscience has higher revenue and earnings than Barinthus Biotherapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.73	-$66.43M	-$1.29	N/A
Aadi Bioscience	$25.07M	3.73	-$65.76M	-$2.35	N/A

Barinthus Biotherapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 531.91%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Barinthus Biotherapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aadi Bioscience had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for Aadi Bioscience and 0 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.00 equaled Aadi Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Aadi Bioscience	Neutral

Barinthus Biotherapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Barinthus Biotherapeutics' return on equity of -63.83% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Barinthus Biotherapeutics has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Summary

Barinthus Biotherapeutics beats Aadi Bioscience on 8 of the 15 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Biomea Fusion?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Barinthus Biotherapeutics currently has a consensus target price of $4.00, indicating a potential upside of 531.91%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 539.10%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Barinthus Biotherapeutics has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market.

In the previous week, Biomea Fusion had 3 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Biomea Fusion and 0 mentions for Barinthus Biotherapeutics. Biomea Fusion's average media sentiment score of 0.35 beat Barinthus Biotherapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Biomea Fusion	Neutral

Barinthus Biotherapeutics' return on equity of -63.83% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Biomea Fusion	N/A	-265.37%	-103.96%

Biomea Fusion has lower revenue, but higher earnings than Barinthus Biotherapeutics. Biomea Fusion is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.73	-$66.43M	-$1.29	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Summary

Biomea Fusion beats Barinthus Biotherapeutics on 10 of the 14 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to China SXT Pharmaceuticals?

Barinthus Biotherapeutics (NASDAQ:BRNS) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

China SXT Pharmaceuticals has lower revenue, but higher earnings than Barinthus Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.73	-$66.43M	-$1.29	N/A
China SXT Pharmaceuticals	$1.14M	89.85	-$6.20M	N/A	N/A

Barinthus Biotherapeutics has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

Barinthus Biotherapeutics currently has a consensus target price of $4.00, indicating a potential upside of 531.91%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Barinthus Biotherapeutics is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for China SXT Pharmaceuticals and 0 mentions for Barinthus Biotherapeutics. China SXT Pharmaceuticals' average media sentiment score of 0.93 beat Barinthus Biotherapeutics' score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
China SXT Pharmaceuticals	Positive

China SXT Pharmaceuticals' return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
China SXT Pharmaceuticals	N/A	N/A	N/A

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

China SXT Pharmaceuticals beats Barinthus Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Barinthus Biotherapeutics' return on equity of -63.83% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Barinthus Biotherapeutics has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Barinthus Biotherapeutics	$14.97M	1.73	-$66.43M	-$1.29	N/A

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Acrivon Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market.

Acrivon Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 566.67%. Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 531.91%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for Acrivon Therapeutics and 0 mentions for Barinthus Biotherapeutics. Acrivon Therapeutics' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Acrivon Therapeutics	Neutral
Barinthus Biotherapeutics	Neutral

Summary

Acrivon Therapeutics beats Barinthus Biotherapeutics on 7 of the 13 factors compared between the two stocks.

Get Barinthus Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRNS vs. The Competition

Export

Metric	Barinthus Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.86M	$3.66B	$6.82B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.49	20.80	27.00	24.20
Price / Sales	1.73	322.97	519.38	94.43
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.35	8.17	10.67	6.26
Net Income	-$66.43M	$23.81M	$3.60B	$331.76M
7 Day Performance	3.26%	-1.12%	-0.32%	-1.10%
1 Month Performance	-4.41%	2.64%	1.88%	-1.26%
1 Year Performance	-67.87%	45.50%	25.50%	18.84%

Barinthus Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRNS Barinthus Biotherapeutics	1.7536 of 5 stars	$0.63 +2.6%	$4.00 +531.9%	-58.2%	$25.86M	$14.97M	N/A	107
SPRO Spero Therapeutics	1.1289 of 5 stars	$1.70 flat	N/A	-39.2%	$98.43M	$66.80M	7.08	150
AADI Aadi Bioscience	N/A	$3.81 -0.8%	N/A	+116.1%	$94.10M	$25.07M	N/A	40	News Coverage
BMEA Biomea Fusion	2.0262 of 5 stars	$1.29 flat	$8.50 +558.9%	-29.2%	$93.27M	N/A	N/A	50
SXTC China SXT Pharmaceuticals	1.0815 of 5 stars	$2.58 +7.1%	N/A	-99.0%	$92.11M	$1.14M	N/A	90	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRNS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. SPRO, AADI, BMEA, SXTC, and ACRV

How does Barinthus Biotherapeutics compare to Spero Therapeutics?

Summary

How does Barinthus Biotherapeutics compare to Aadi Bioscience?

Summary

How does Barinthus Biotherapeutics compare to Biomea Fusion?

Summary

How does Barinthus Biotherapeutics compare to China SXT Pharmaceuticals?

Summary

How does Barinthus Biotherapeutics compare to Acrivon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. SPRO, AADI, BMEA, SXTC, and ACRV

How does Barinthus Biotherapeutics compare to Spero Therapeutics?

Which has more risk and volatility, SPRO or BRNS?

Do analysts prefer SPRO or BRNS?

Which has stronger valuation and earnings, SPRO or BRNS?

Do insiders & institutionals hold more shares of SPRO or BRNS?

Does the media favor SPRO or BRNS?

Is SPRO or BRNS more profitable?

Summary

How does Barinthus Biotherapeutics compare to Aadi Bioscience?

Do insiders & institutionals have more ownership in BRNS or AADI?

Which has preferable earnings & valuation, BRNS or AADI?

Do analysts rate BRNS or AADI?

Does the media favor BRNS or AADI?

Is BRNS or AADI more profitable?

Which has more volatility & risk, BRNS or AADI?

Summary

How does Barinthus Biotherapeutics compare to Biomea Fusion?

Do analysts recommend BRNS or BMEA?

Do insiders and institutionals believe in BRNS or BMEA?

Which has more volatility & risk, BRNS or BMEA?

Does the media refer more to BRNS or BMEA?

Is BRNS or BMEA more profitable?

Which has higher earnings and valuation, BRNS or BMEA?

Summary

How does Barinthus Biotherapeutics compare to China SXT Pharmaceuticals?

Which has higher earnings & valuation, BRNS or SXTC?

Which has more volatility & risk, BRNS or SXTC?

Do analysts rate BRNS or SXTC?

Does the media refer more to BRNS or SXTC?

Is BRNS or SXTC more profitable?

Do insiders & institutionals hold more shares of BRNS or SXTC?

Summary

How does Barinthus Biotherapeutics compare to Acrivon Therapeutics?

Is ACRV or BRNS more profitable?

Which has higher earnings & valuation, ACRV or BRNS?

Do institutionals & insiders have more ownership in ACRV or BRNS?

Which has more risk and volatility, ACRV or BRNS?

Do analysts prefer ACRV or BRNS?

Does the media prefer ACRV or BRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools